The FDA's preliminary evaluation as of January 13, 2026, had not found evidence that GLP-1 receptor agonists cause suicidal thoughts or actions, and the FDA requested removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist medications used for weight management, stating their evaluation didn't identify an increased risk.

factualpending

Speaker

Dr. Amin Dadgar

Evidence Quote

“As of January 13th, 2026, the FDA stated their preliminary evaluation had not found evidence that these medicines cause suicidal thoughts or actions.”

Source

Ozempic & Mounjaro: Same Shot. Opposite Results.— Dr. Amin Hedayat, MD
Created: 8/12/2026, 6:40:36 PM

Your notes

Loading notes...